argenx (NASDAQ:ARGX) Rating Lowered to Hold at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft lowered shares of argenx (NASDAQ:ARGX - Free Report) from a buy rating to a hold rating in a research report released on Friday, MarketBeat reports.

Other research analysts have also issued reports about the stock. HC Wainwright raised their price objective on shares of argenx from $504.00 to $533.00 and gave the company a buy rating in a research note on Friday, July 26th. Wedbush raised their price objective on shares of argenx from $519.00 to $560.00 and gave the company an outperform rating in a research note on Friday, July 26th. Oppenheimer raised shares of argenx from a market perform rating to an outperform rating and set a $546.00 price objective on the stock in a research note on Tuesday, July 23rd. Guggenheim reissued a buy rating and set a $585.00 price target on shares of argenx in a research report on Thursday, September 26th. Finally, JPMorgan Chase & Co. raised their price target on shares of argenx from $500.00 to $640.00 and gave the company an overweight rating in a research report on Friday, August 23rd. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus price target of $543.28.

argenx Price Performance

Shares of ARGX traded down $13.04 during trading hours on Friday, hitting $529.95. 310,323 shares of the stock were exchanged, compared to its average volume of 317,125. argenx has a fifty-two week low of $327.73 and a fifty-two week high of $554.74. The business has a 50-day moving average of $525.00 and a 200-day moving average of $442.04. The firm has a market capitalization of $31.50 billion, a P/E ratio of -95.93 and a beta of 0.62.

argenx (NASDAQ:ARGX - Get Free Report) last issued its earnings results on Thursday, July 25th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $1.34. The business had revenue of $489.43 million for the quarter, compared to analyst estimates of $436.66 million. argenx had a negative net margin of 12.31% and a negative return on equity of 7.33%. During the same period in the prior year, the firm earned ($1.69) earnings per share. As a group, analysts forecast that argenx will post -0.37 earnings per share for the current fiscal year.

Institutional Trading of argenx

A number of large investors have recently added to or reduced their stakes in ARGX. Price T Rowe Associates Inc. MD lifted its stake in shares of argenx by 49.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,504,506 shares of the company's stock valued at $2,167,235,000 after buying an additional 1,830,651 shares in the last quarter. Janus Henderson Group PLC lifted its stake in shares of argenx by 24.8% during the 1st quarter. Janus Henderson Group PLC now owns 2,216,648 shares of the company's stock valued at $872,690,000 after buying an additional 439,889 shares in the last quarter. Avoro Capital Advisors LLC lifted its stake in shares of argenx by 23.5% during the 4th quarter. Avoro Capital Advisors LLC now owns 1,234,567 shares of the company's stock valued at $469,666,000 after buying an additional 234,567 shares in the last quarter. RTW Investments LP lifted its stake in shares of argenx by 31.5% during the 4th quarter. RTW Investments LP now owns 667,195 shares of the company's stock valued at $253,821,000 after buying an additional 160,000 shares in the last quarter. Finally, Clearbridge Investments LLC lifted its stake in shares of argenx by 36.5% during the 1st quarter. Clearbridge Investments LLC now owns 596,277 shares of the company's stock valued at $234,766,000 after buying an additional 159,480 shares in the last quarter. Hedge funds and other institutional investors own 60.32% of the company's stock.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.